Inclusion Criteria:  At least 2 positive MAC sputum cultures in the last 12 months with at least one AFB positive sputum obtained within 12 weeks prior to randomization Meet American Thoracic Society (ATS)/ Infectious Disease Society of America (IDSA) 2007 pulmonary clinical disease criteria[1] Age 18 and older Diagnosis of Bronchiectasis and/or bronchiectatic findings evident on chest CT report Ability to provide informed consent  Exclusion Criteria:  Any patient who is unwilling or unable to provide consent or to comply with this protocol Cavitary NTM disease Patients who are currently taking or within the prior 6 months received any of the following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy (macrolide, ethambutol, rifampin) for MAC treatment Diagnosis of HIV Diagnosis of Cystic fibrosis Active pulmonary tuberculosis, fungal, or nocardial disease requiring treatment at screening Current use of chronic systemic corticosteroids at doses of 15 mg/day for more than 3 months Prior lung or other solid organ transplant